Mode
Text Size
Log in / Sign up
Phase 3 N=500 Randomized Single-blind Treatment

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Colonoscopy

Enrolled (actual)
500
Serious AEs
0.4%
Results posted
Oct 2023
Primary outcome: Primary: Proportion of Subjects With Successful Bowel Preparation — 212; 211 Participants — p=<0.001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Bowel Prep (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Braintree Laboratories
Primary completion
Jan 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Subjects With Successful Bowel Preparation
212; 211 <0.001 sig

Summary

The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

Eligibility Criteria

Inclusion Criteria

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
  • 18 to 85 years of age (inclusive)
  • If female, and of child-bearing potential, is using an acceptable form of birth control.
  • Negative serum pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
  • Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation
  • Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.
  • Subjects with uncontrolled hypertension.
  • Subjects taking antibiotics within 7 days of colonoscopy.
  • Subjects with severe renal, hepatic or cardiac insufficiency.
  • Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
  • Subjects undergoing insulin therapy for any indication.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects undergoing colonoscopy for foreign body removal and/or decompression.
  • Subjects taking tricyclic antidepressants.
  • Subjects using drugs of abuse, including abused prescription medications.
  • Subjects who are withdrawing from alcohol or benzodiazepines.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04446312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search